drugset / Trial / NCT00182455

Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP)

NCT00182455

RandomizedParallel-groupQuadruple-blindTreatment

Summary

SSRI's are considered first-line treatments for GSP, however many patients continue to have significant symptoms despite an adequate trial of an SSRI. Topiramate, a drug, which targets the glutamate system in the brain, has been shown to improve symptoms of social phobia when used on its own and has also been used as an additive treatment in other anxiety disorders. This study will test the efficacy of adding topiramate to a subject's current SSRI in cases of GSP which are considered to be treatment-resistant.

Timeline

Start
2004-03-01
Primary completion
2018-12-01
Completion
2018-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Topiramate Small molecule

Indications